TheraRadar
← Back
Data updated: Jun 28, 2026

ACTELION

Big Pharma
CardiovascularRespiratoryNeurology Execution: Good

ACTELION is a major pharmaceutical company focused on Cardiovascular, Respiratory, Neurology. Key products include OPSUMIT.

2001
Since
7
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
6 Small Molecules

ACTELION at a Glance

  • Leading 6 drug targets across portfolio
  • Fast trial execution (23 months median completion)

Upcoming FDA Decisions

Full Calendar →
Jan 20, 2027 — Foundayo (orforglipron)

ACTELION's Key Drugs

ACTELION's core commercial portfolio centers on OPSUMIT, UPTRAVI, OPSYNVI, spanning Cardiovascular and Respiratory — its most strategically important drugs approved in the last 15 years.

OPSUMIT
Cardiovascular

Pulmonary Arterial Hypertension

ETA Approved 2013
UPTRAVI
Cardiovascular

Pulmonary Arterial Hypertension

Prostacyclin receptor Approved 2015
OPSYNVI
Cardiovascular

Pulmonary Arterial Hypertension

ETA Approved 2024

ACTELION's Recent FDA Approvals

New NDA/BLA approvals for ACTELION over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ACTELION's Therapeutic Areas

ACTELION's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 45%
5 drugs Phase 3: 33 Phase 2: 10 Phase 1: 10
Respiratory 45%
5 drugs Phase 3: 32 Phase 2: 12 Phase 1: 10
Neurology 4%
0 drugs Phase 3: 3 Phase 2: 2
Infectious Disease 3%
0 drugs Phase 3: 2 Phase 2: 2 Phase 1: 1
Gastroenterology 2%
0 drugs Phase 3: 2 Phase 1: 1

ACTELION Pipeline Snapshot

ACTELION has 120 active clinical programs from ClinicalTrials.gov — 72 Phase 3, 26 Phase 2 and 22 Phase 1.

72
Phase 3
26
Phase 2
22
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q1 2027
Macitentan
Hypertension, Pulmonary
Estimated · fresh NCT05179876
Q4 2025
Macitentan 10 mg
Pulmonary Arterial Hypertension
Completed · awaiting NCT04273945

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OPSUMIT leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 27/41 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges